EUCTR2005-000053-30-IT进行中（未招募）不适用
A RANDOMIZED PHASE 2 STUDY OF THE ANTI-ANGIOGENESIS AGENT AG-013736 IN COMBINATION WITH GEMCITABINE IN PATIENTS WITH CHEMOTHERAPY-NAIVE ADVANCED PANCREATIC CANCER PRECEDED BY A PHASE 1 PORTIO
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- PFIZER
- 入组人数
- 102
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A randomized phase 2 study of the anti-angiogenesis agent AG-013736 in combination with gemcitabine in patients with chemotherapy-naïve advanced pancreatic cancer preceded by a phase 1 portion - N/ATreatment of patients with chemotherapy-naïve, locally advanced or metastatic epithelial cancer of the exocrine pancreasMedDRA version: 5.1Level: LLTClassification code 10033604EUCTR2005-000053-30-ESPfizer, S.A.102
进行中（未招募）
不适用
A randomized phase 2 study of the anti-angiogenesis agent AG-013736 in combination with gemcitabine in patients with chemotherapy-naïve advanced pancreatic cancer preceded by a phase 1 portioTreatment of patients with chemotherapy-naïve, locally advanced or metastatic epithelial cancer of the exocrine pancreasMedDRA version: 5.1Level: LLTClassification code 10033604EUCTR2005-000053-30-BEPfizer Inc. - La Jolla laboratories102
进行中（未招募）
不适用
A randomized phase 2 study of the anti-angiogenesis agent AG-013736 in combination with gemcitabine in patients with chemotherapy-naïve advanced pancreatic cancer preceded by a phase 1 portioEUCTR2005-000053-30-DEPfizer Pharma GmbH102
进行中（未招募）
1 期
A randomized phase 2 study of the anti-angiogenesis agent AG-013736 in combination with gemcitabine in patients with chemotherapy-naïve advanced pancreatic cancer preceded by a phase 1 portioTreatment of patients with chemotherapy-naïve, locally advanced or metastatic epithelial cancer of the exocrine pancreasMedDRA version: 5.1 Level: LLT Classification code 10033604EUCTR2005-000053-30-GBPfizer Inc. - La Jolla laboratories102
进行中（未招募）
不适用
A PIVOTAL PHASE 2 STUDY OF THE ANTI-ANGIOGENESIS AGENT AG-013736IN PATIENTS WITH 131I-REFRACTORY METASTATIC OR UNRESECTABLELOCALLY-ADVANCED PAPILLARY, FOLLICULAR, OR HURTHLE-CELL THYROID CANCER WHO ARE ALSO REFRACTORY TO, OR INTOLERANT OF,OR HAVE CLINICAL CONTRAINDICATION TO, DOXORUBICIN TREATMENT - NDTreatment of patients with 131I-refractory metastatic or unresectable locally-advancedpapillary, follicular, or Hurthle-cell thyroid cancer who are also refractory to, or intolerant of,or have clinical contraindication to, doxorubicin treatment.MedDRA version: 9.1Level: LLTClassification code 10055107Term: Thyroid cancer metastaticEUCTR2006-002576-18-ITPFIZER100